BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28965624)

  • 1. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
    Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z
    Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
    Yang Y; Lu S; Zeng W; Xie S; Xiao S
    Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
    Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
    Hafez NH; Shaaban HM
    Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
    Lew M; Pang JC; Jing X; Fields KL; Roh MH
    Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens.
    Braxton DR; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2015 Apr; 43(4):271-7. PubMed ID: 25088841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers of metastatic carcinoma of breast origin.
    Gown AM; Fulton RS; Kandalaft PL
    Histopathology; 2016 Jan; 68(1):86-95. PubMed ID: 26768031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas.
    Liu H; Shi J; Prichard JW; Gong Y; Lin F
    Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups.
    Ni YB; Tsang JY; Chan SK; Tse GM
    Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
    Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
    Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
    Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
    Wendroth SM; Mentrikoski MJ; Wick MR
    Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA3 as a putative marker of breast cancer metastasis-A retrospective immunohistochemical study.
    De Lara S; Parris TZ; Werner Rönnerman E; Helou K; Kovács A
    Breast J; 2018 Mar; 24(2):184-188. PubMed ID: 28703335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative expression of TRPS1, GATA3, SOX10, mammaglobin, and GCDFP-15 in effusion specimens with breast carcinoma.
    Bradt A; Jing X; Smola BS; Lew M
    Diagn Cytopathol; 2023 Nov; 51(11):665-673. PubMed ID: 37461248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer.
    Huo L; Zhang J; Gilcrease MZ; Gong Y; Wu Y; Zhang H; Resetkova E; Hunt KK; Deavers MT
    Histopathology; 2013 Jan; 62(2):267-74. PubMed ID: 22963676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract.
    O'Connell FP; Wang HH; Odze RD
    Arch Pathol Lab Med; 2005 Mar; 129(3):338-47. PubMed ID: 15737028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology.
    Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U
    Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATA-binding protein 3 in non-small-cell lung cancer.
    Kriegsmann K; Zgorzelski C; Muley T; Christopoulos P; von Winterfeld M; Herpel E; Goeppert B; Mechtersheimer G; Sinn P; Stenzinger A; Schirmacher P; Winter H; Eichinger M; Warth A; Kriegsmann M
    Histopathology; 2020 Dec; 77(6):900-914. PubMed ID: 32634256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry.
    Huo L; Gong Y; Guo M; Gilcrease MZ; Wu Y; Zhang H; Zhang J; Resetkova E; Hunt KK; Deavers MT
    Histopathology; 2015 Aug; 67(2):245-54. PubMed ID: 25564996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.